Overview of benefit/risk of biological agents

Anna K. Imperato, Clifton O. Bingham, Steven B. Abramson

Research output: Contribution to journalReview article

Abstract

Targeted tumor necrosis factor-α antagonists, first approved by the FDA in 1998, have had a significant impact on the treatment of patients with rheumatoid arthritis. In general, the benefit/risk ratio for these agents and the IL-1 receptor antagonist, anakinra, has been quite favorable. However, infrequent adverse events can be serious and require continued Pharmacovigilance. Infections, particularly tuberculosis and less commonly fungal infections, are among the most serious adverse events, especially given delays in diagnosis due to subtle or atypical presentations. Questions have also arisen regarding whether anti-TNF-α agents increase the risk of lymphoma, a complicated issue confounded by the multiple risk factors for lymphoma in patients with rheumatoid arthritis and low observed incidence rates of lymphoma, requiring prolonged monitoring. Additional rare reported complications include systemic lupus erythematosus-like syndromes, congestive heart failure and demyelinating syndromes (including cases resembling progressive multifocal leukoencephalopathy). Ongoing post-marketing surveillance of these and other serious adverse events is necessary to determine the true incidence rates, and whether a reassessment of the overall risk-benefit of tumor necrosis factor-α antagonists will be required.

Original languageEnglish (US)
Pages (from-to)S108-S114
JournalClinical and experimental rheumatology
Volume22
Issue number5 SUPPL. 35
StatePublished - Oct 18 2004
Externally publishedYes

Keywords

  • Demyelination
  • Drug-induced lupus
  • Heart failure
  • Infections
  • Lymphoma
  • Rheumatoid arthritis
  • TNF-α antagonists

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Overview of benefit/risk of biological agents'. Together they form a unique fingerprint.

  • Cite this

    Imperato, A. K., Bingham, C. O., & Abramson, S. B. (2004). Overview of benefit/risk of biological agents. Clinical and experimental rheumatology, 22(5 SUPPL. 35), S108-S114.